Bd receives fda emergency use authorization for covid-19, influenza a/b, rsv combination test

Single test on bd max™ molecular diagnostic system identifies and differentiates multiple respiratory infectious diseases franklin lakes, n.j. , feb. 8, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that it has received emergency use authorization from the u.s. food and drug administration (fda) for a new molecular diagnostic combination test for sars-cov-2, influenza a + b and respiratory syncytial virus (rsv) to help combat illness in the current and future respiratory virus seasons.
BDX Ratings Summary
BDX Quant Ranking